N/A
Completed N=795
Association of Hepatitis C Virus With Breast Cancer
Source: ClinicalTrials.gov NCT04090164 ↗Enrolled (actual)
795
Serious AEs
—
Results posted
Oct 2020
Primary outcomePrimary: Prevalence of HCV Seropositivity in Breast Cancer Patients. — 88; 15; 317; 130 Participants — p=0.0027
Summary
Hepatitis C viral infection is a major health problem in Egypt. The management of breast cancer patients is often complicated by the presence of associated HCV infection. This study aims at investigating the epidemiological association of the two conditions. It will also investigate the possible correlation with treatment outcome.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Prevalence of HCV Seropositivity in Breast Cancer Patients. |
88; 15; 317; 130 | 0.0027 sig |
| SECONDARY Disease-related Events |
37; 6 | — |
Eligibility Criteria
Inclusion Criteria
- Biopsy-proven invasive breast cancer.
Exclusion Criteria
- Patients with unknown viral marker status.
- Patients who did not complete their management at OCMU.
- Patients with multiple cancer diagnoses.
- Patients with virus-unrelated hepatic pathology.
Data sourced from ClinicalTrials.gov (NCT04090164). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.